Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Energenesis Biomedical CoTPE:6657 -2.79%62 3-Year ROIIC % is 8.44 as of Dec. 2025, which is 97% below its 10-year median of 274.70. GuruFocus rates TPE:6657 with a GF Score™ of 62/100 and a GF Value™ of NT$51.55 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 1,319 Biotechnology companies, Energenesis Biomedical Co ranks better than 60.5% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Energenesis Biomedical Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 8.44%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Energenesis Biomedical Co's 3-Year ROIIC % or its related term are showing as below:
TPE:6657's 3-Year ROIIC % is ranked better than 60.5% of 1319
companies
in the Biotechnology industry
Industry Median: -4.85
vs TPE:6657: 8.44
Energenesis Biomedical Co (TPE:6657) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Energenesis Biomedical Co 3-Year ROIIC % Related Terms
Energenesis Biomedical Co 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:6657 vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Energenesis Biomedical Co's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Energenesis Biomedical Co 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Energenesis Biomedical Co's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Energenesis Biomedical Co's 3-Year ROIIC % falls into.
Energenesis Biomedical Co 3-Year ROIIC % Calculation
Energenesis Biomedical Co's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -275.275 (Dec. 2025) - -271.654 (Dec. 2022) )
/
( 90.367 (Dec. 2025) - 133.279 (Dec. 2022) )
=
-3.621
/
-42.912
=
8.44%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Energenesis Biomedical Co (TPE:6657) has a 3-Year ROIIC % of 8.44 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Energenesis Biomedical Co and its competitors. This is 97% below median its historical median of 274.70. According to the industry distribution chart, Energenesis Biomedical Co ranks #521 out of 1319 companies in the Biotechnology industry, placing it in the top 39.5%.
Is Energenesis Biomedical Co's 3-Year ROIIC % too high?
Energenesis Biomedical Co's current 3-Year ROIIC % of 8.44 is 97% below median its 10-year median of 274.70. Based on the distribution chart, Energenesis Biomedical Co ranks #521 out of 1319 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Energenesis Biomedical Co has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Energenesis Biomedical Co's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Energenesis Biomedical Co ranks #521 out of 1319 companies for 3-Year ROIIC %. This puts Energenesis Biomedical Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Energenesis Biomedical Co and its competitors. Energenesis Biomedical Co's current 3-Year ROIIC % is 8.44, which is 97% below median its own 10-year median of 274.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Energenesis Biomedical Co stock overvalued right now?
Based on GuruFocus' analysis, Energenesis Biomedical Co (TPE:6657) is currently considered Possible Value Trap. The stock's GF Value™ is NT$51.55, compared to a current price of NT$33.05 — trading 35.9% below its estimated fair value. The current 3-Year ROIIC % is 8.44, which is 97% below median its 10-year median of 274.70. Energenesis Biomedical Co's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Energenesis Biomedical Co (TPE:6657), the current 3-Year ROIIC % is 8.44 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Energenesis Biomedical Co (TPE:6657) Overvalued in 2026?
Based on GuruFocus' analysis, Energenesis Biomedical Co stock appears to be undervalued.
The current stock price of NT$33.05 is trading 35.9% below its estimated GF Value™ of NT$51.55.
GuruFocus considers Energenesis Biomedical Co to be Possible Value Trap.
Key valuation signals for TPE:6657:
3-Year ROIIC %: 8.44 (97% below median its 10-year median of 274.70)
GF Value™: NT$51.55 vs. price of NT$33.05 (35.9% below fair value)
No single metric tells the full story. See the TPE:6657 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Energenesis Biomedical Co Ltd is a biomedicine company. The company is engaged in businesses related to biological experimentation and analysis, as well as new drugs development. The company uses its ENERGI drug development platform to activate AMP-activated protein kinase (AMPK), a key enzyme in cell energy regulation, as a means of developing disease treatments. The product pipeline of the company consists of ENERGI-F703, a diabetic foot ulcers treatment gel; ENERGI-F701, a product developed for male hair loss; ENERGI-F704, an inflammatory bowel disease treatment; and ENERGI-F711, a burn cream,F708, Asthama treatment, and others.
62GF Score
Get the complete analysis for TPE:6657
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6657 has been successfully added to your 
